Back HIV Populations Pregnancy & MTCT

Pregnancy & HIV MTCT

AIDS 2016: Study Looks at Use of HIV PrEP Before and During Pregnancy and Breastfeeding

Truvada for pre-exposure prophylaxis (PrEP) when it was offered as an additional tool for preventing HIV infection during the pre-conception period, pregnancy, and breastfeeding, according to study findings presented at the 21st International AIDS Conference (AIDS 2016) last month in Durban and published in the July 19 online edition of the American Journal of Obstetrics and Gynecology.

alt

Read more:

AIDS 2016: Early HIV Treatment -- Mothers Say They Need Time to Think

Findings from the first randomized controlled trial to date evaluating postpartum antiretroviral therapy (ART) for women with high CD4 cell counts (over 400 cells/mm3) highlight a critical need to increase treatment acceptance in this population, according to research presented at the 21st International AIDS Conference (AIDS 2016) last week in Durban.

alt

Read more:

CROI 2016: Studies Probe Retention in Care for HIV+ Women Who Start ART During Pregnancy

Engaging lay counselors to provide a combination package of evidence-based interventions in Nyanza, Kenya, and addressing partner disclosure, as well as pre-treatment education about the benefits of antiretroviral therapy (ART) for maternal and child health in Malawi’s Option B+ program improved retention in care and reduced loss to follow-up of mothers with HIV and their infants, studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) show.

alt

Read more:

AIDS 2016: South Africa Has Driven Mother-to-Child HIV Transmission Down to 4%

Mother-to-child transmission (MTCT) of HIV at a population level was just over 4% at 18 months of follow-up in a national evaluation in South Africa, Ameena Goga, presenting on behalf of the South African prevention of mother-to-child transmission Evaluation Group, told participants at the 21st International AIDS Conference (AIDS 2016) this week in Durban. 

alt

Read more:

CROI 2016: Cotrimoxazole Prophylaxis Provides No Benefit for HIV-Exposed Uninfected Children

Challenging current guidelines, prolonged use of cotrimoxazole may not be necessary for HIV-exposed but uninfected children in low-mortality, non-malarial settings with low risk for late mother-to-child transmission throug breastfeeding, Roger Shapiro told participants at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

alt

Read more: